Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to evaluate the durability of protection of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Jun Zhang
Collaborators
NCT06157151 · Cervical Cancer, HPV-Related Carcinoma, and more
NCT06952660 · Cervical Cancer
NCT04895709 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, and more
NCT05108298 · Breast Cancer, NOS, CNS Primary Tumor, NOS, and more
NCT05952141 · Cervical Cancer
Peking University People's Hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions